medigraphic.com

2005, Number 3

<< Back Next >>

Anales de Radiología México 2005; 4 (3)

Stromal tumors of the digestive tube: Radiologic experience of the Nutrition National Institute

Kimura HET, Vázquez-Lamadrid J, Téliz-Meneses MA

Language: Spanish
References: 23
Page: 255-269
PDF size: 322.60 Kb.


ABSTRACT

Introduction: The most common neoplasia of the digestive tube are gastrointestinal stomach tumors. These tumors are caused and has an origin in the muscularis propria. They are characterized by immunohistochemical expressions of the transmembrane receptor of the c-kit protooncogen and of the CD34 marker.
Purpose: To acknowledge the way of presenting the radiological and clinical characteristics of gastrointestinal stomach tumors (GITS).
Material and methods: A search in the clinical file of the Institute INCMNSZ was made, from 1980 to September 2005, of all mesenchymatous tumors of the gastrointestinal duct. 79 patients were found with mesenchymatous tumors, only those with c-kit or CD 34+ or included.
Results: The age range was 75.4 years (24-82 years old). The stomach was one of the main sites of affection (15/28 injuries, 53.6%), along with small intestine (ID) (9/28 tumors, 32.2%) and the mesenteron/serous (2/28) injuries, 7.1%). Hemorrhage or bleeding on the digestive duct was high due to the main form of presentation in the GITS (66%, 10/15 injuries and ID (60%, 6/9 injuries).
Analysis: Stromal tumors are normally shown in older people raging from 50 years old, predominating on the male patients from 2:1. Incidence is estimated in 10 to 20 cases per million. These neoplasia affect particularly all the digestive tube, from the esophagus up to the anus.
Conclusions: GITS are the tumors caused in the muscularis propria. The stomach is the most frequent location. Metastasis site are more frequent in the liver and peritoneum. Neoplasia are considered between › 5 cm and with necrosis areas.


REFERENCES

  1. Sharp RM, et al. Gastrointestinal stromal tumor (best cases from the AFIP). Radiographics 2001; 21: 1557-60.

  2. Levy AD, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003; 23: 283-304.

  3. Burkill GJ, et al. Malignant gastrointestinal stromal tumor: Distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-32.

  4. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM 2001; 344: 1084-6.

  5. Joensuu H, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEJM 2001; 344: 1052-6.

  6. Demetri GD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472-80.

  7. Levy AD, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis: Imaging features with clinicopathologic correlation. AJR 2004; 183: 1629-36.

  8. Sinha R, et al. Mesenteric gastrointestinal Stromal tumor in a patient with neurofibromatosis. AJR 2004; 183: 1844-6.

  9. Nishida T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR 2003; 180: 185-9.

  10. Rioux M, Mailloux C. Crescent-shaped necrosis: A new imaging sign suggestive of stromal tumor of small bowel. Abdom Imaging 1997; 22: 376-80.

  11. Fortman BJ. Torricelli-Bernoulli. Sign in an ulcerating gastric leiomyosarcoma. AJR 1999; 173: 199-200.

  12. Choi H, et al. CT evaluation of the response of gastrointestinal stromal tumors after Imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR 2004; 183: 1619-28.

  13. Kim HC, et al. Gastrointestinal stromal tumors of the stomach: CT findings and prediction of malignancy. AJR 2004; 183: 893-8.

  14. Kim HC, et al. Gastrointestinal stromal tumors of the duodenum: CT and Barium Study Findings. AJR 2004; 183: 415-19.

  15. Ba-Ssalamah A, et al. Dedicated multidetector CT of the stomach: Spectrum of diseases. Radiographics 2003; 23: 625-44.

  16. Kim HC, et al. Primary gastrointestinal stromal tumors in the omentum and mesentery: CT findings and pathologic correlation. AJR 2004; 182: 1463-7.

  17. Levy AD, et al. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR 2003; 180: 1607-12.

  18. Pickhardt PJ, Bhalla S. Primary neoplasms of the peritoneal and subperitoneal origin: CT findings. Radiographics 2005; 25: 983-95.

  19. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.

  20. van Oosterom AT, Judson I, Vermeij J, et al. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 2001; 358: 1421-3.

  21. Miller AB, Hoogstraten B, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.

  22. Chen MY, et al. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (Imatinib Mesylate). AJR 2002; 179: 1059-62.

  23. Zonios D, et al. Cyst-like hepatic metastases from gastrointestinal stromal tumors could be seen before any treatment. AJR 2003; 181: 282 (carta al editor).




2020     |     www.medigraphic.com